Skip to main content
. 2018 Jun 8;1(2):e180219. doi: 10.1001/jamanetworkopen.2018.0219

Table 1. Patient Characteristics.

Clinical Characteristic Prostate Cancer Negative (n = 365) Prostate Cancer Positive (n = 655)a P Value Total (N = 1020)
Age, median (IQR), y 64 (59-69) 68 (62-72) <.001 67 (61-71)
PSA, median (IQR), ng/mL 6.4 (5.2-8.9) 9.2 (6.1-19.9) .03 8.0 (5.7-13.0)
Prostate volume, median (IQR), cm3 65 (49-88) 47 (36-61) <.001 53 (40-72)
PSA density, median (IQR), ng/mL/cm3 0.10 (0.07-0.14) 0.20 (0.12-0.43) <.001 0.15 (0.10-0.27)
Time from bpMRI to biopsy, median (IQR), d 7 (4-11) 7 (5-9) .44 7 (7-9)
cTDRE stage, No. (%)
Nonpalpable tumor <.001b
Tx 106 (29) 69 (11) 175 (17)
T1c 208 (57) 260 (40) 468 (46)
Palpable tumor
T2 46 (13) 199 (30) 245 (24)
T3 5 (1) 120 (18) 125 (12)
T4 0 7 (1) 7 (1)

Abbreviations: bpMRI, biparametric magnetic resonance imaging; cTDRE, tumor stage determined by digital rectal examination; IQR, interquartile range; PSA, prostate-specific antigen.

SI conversion factor: To convert PSA to micrograms per liter, multiply by 1.0.

a

Based on biopsy results of combined biopsies in all men.

b

A Fisher exact test was used to compare the cTDRE stage pooled in nonpalpable and palpable tumor groups.